This study was conducted with the objective of determining whether patient self-reported functioning in key domains of daily living differs by pain severity and analgesic treatment among older adults with OA in Spain. To do this, the data from the latest available ENSE survey were used [22]; this could be considered a strength of this study due to the large size of the sample analyzed and its nationwide representability, despite the fact that data capture was based on persons surveyed. Nonetheless, self-rated OA severity and other outcomes, including pain, function, productivity, and costs in both United States and European populations suggest that self-reporting of OA severity provides an accurate and tangible assessment of patients’ perceptions of their disease [15,34,35]. Another strength of using the ENSE survey was that the self-reported prevalence of OA was more or less the same as the physician-based Spanish prevalence study of rheumatologic diseases (the EPISER study) conducted recently by the Spanish Association of Rheumatology [36]; the prevalence of OA in persons aged 40 or older was 29.4% in the EPISER study versus 29.8% in the ENSE survey in the same age group. In the analysis included here, a large sample comprising a total of 3,389 OA patients aged 65 or older was analyzed, given that the ENSE only examines the variables that were objective of this study in that age group. However, while analysis was restricted to this population, it is ultimately the population that is most representative of osteoarthritis; 67.4% of patients with self-reported OA in Spain are 65 years of age or older, and the figure is similar to that seen in the EPISER study [22, 36]. Also, the study analyzed up to five different key domains of patient functioning in daily life; that too could be considered as a strength of this study as, to the best of our knowledge, there are no existing similar studies in the Spanish population.
As OA is a heterogeneous disease, several limitations of this study are to be pointed out. First, it lacks detailed data with regard to OA location; second, it lacks data regarding whether OA affects a single joint or several joints; third, it lacks a radiographic assessment scale; and fourth, it lacks data about the relationship between OA and other comorbidities and their relationship to the functional impairment found. Moreover, it must be taken into account that the survey collected information on pharmacological analgesic treatment of OA in a generic fashion (treated or not treated with usual analgesics in the last two weeks), but lacked detailed information on active substances, doses, etc., as well as information regarding non-pharmacological treatment (which is central to OA treatment). Those data were not reported in the survey; moreover, the data in the survey are self-reported by survey participants rather than drawn from medical databases or directly from medical personnel. Furthermore, although the size of the sample analyzed was large, some subgroups of patients (particularly OA subjects with untreated severe pain) could be under-represented in the study.
Regarding the comparability of this analysis, a similar study was conducted by Stamm et al. in Austria [21]. That study focused on activities of daily living alone; however, it did analyze the impact of pain. Our study of functional capacity found that these patients have a considerable degree of limitation in carrying out both basic and instrumental activities of daily living, mainly those with severe pain. Mobility (walking and up/downstairs) and hard housekeeping were the specific activities most seriously impacted by OA pain and accounted for the most weight (around 17–23% per item) in the total scores for BADLs and IADLs, respectively, when compared with other items in such domains. In addition, patients with OA experienced restriction and decline in other essential functions such as cognition, social functioning and mental health. In all these domains of functioning, a significant association was found between pain severity and impairment, such that the higher the pain, the higher the impairment, regardless of treatment status; this points to an increased need for external care. All OA patients with severe pain in the ENSE survey declared they were dependent to some degree of external caregiver care for both BADLs and IADLs. In addition, OA subjects treated with common analgesics showed significantly higher impairment in BADLs, IADLs, and social functioning, particularly subjects with moderate or severe pain; limitation of social functioning was as high as 42% compared with 32% in the group of patients not treated with analgesia. The study by Stamm et al. [21] also found a significant association between pain severity and impact thereof on both BADLs and IADLs in older adults with OA among other disorders. The European Project on OSteoArthritis (EPOSA study), aimed at investigating the consequences of the most common forms of OA in older adults using data from six European countries, including Spain [37], found that clinical OA, present in one or two sites (hip and knee), or in two or three sites (hip, knee, and hand), increased the risk of social isolation, cognitive impairment and worse walking and physical activity [38, 39]. These findings are consistent with our analysis, particularly in the moderate to severe pain group, although the EPOSA study did not analyze whether the presence of pain interferes with activities of daily living [40]. Likewise, more severe and stable joint pain levels were found to be associated with anxiety and depressive symptoms in older persons with OA [41]; this is fairly consistent with the impairment in mental functioning found in the analysis of older Spanish subjects with OA included in the 2017 ENSE survey. Research aiming to demonstrate that individuals with OA are more likely to experience impairment in their ability to perform activities of daily living has been seen previously, but in selected populations and mainly on patients with OA in specific health settings or on waiting lists for joint replacement [17–20]. Recently, persistent opioid users were found to be more likely than non-users to report limitations in IADLs and physical, social, and cognitive functioning in follow-up [42]. Our analysis is also consistent with data regarding poorer patient functioning in BADLs, IADLs, and social functioning in subjects using analgesic drugs, although the ENSE survey was not able to identify active substances in analgesic agents used by patients. Given the nature of this study, not allowing to see a cause–effect relationship, it is possible that treated patients had more severe joint destruction; it is also possible that treated patients had developed a phenomena of secondary central sensitization to pain, due to a failure to achieve optimal pain management, perhaps because they had partially responded or not responded to conventional analgesic therapies, and other psychopathological reasons. Although not evaluated in this survey, frailty, defined as a geriatric syndrome that involves loss of functioning and is a prognostic factor for disability [43], might have been present in a significant percentage of these patients, given the impairment observed in activities of daily living and mental function, which might have been correlated with low physical activity, overall weakness, exhaustion and overall slowness [43].
The gender analysis showed similar findings. Due to limitations in sample sizes, differences did not reach statistical significance in some comparisons; regardless, our analysis failed to find significant differences between treated and untreated patients within the subset of patients with meaningful limitation (the most impaired category) in each of the key domains of functioning analyzed in this study, although this subset was larger in treated subgroups. Nonetheless, the association between pain severity and percentage of OA patients with significant limitation was present in each of the domains of functioning evaluated, with significantly more subjects with meaningful restriction in the severe pain category subgroup. Also, clinical OA was associated with frailty and pre-frailty in older adults in European countries [37].
The prevalence and burden of OA is growing as both population aging and obesity rates rise; this means that the viability of joint replacement programs will be at risk by 2030. Unmet needs exist regarding not only disease progression modifiers but also pain management. Hence, this disease merits more attention, not only from medical researchers, but also from healthcare policymakers, who must work towards coordinating a holistic approach that includes comprehensive OA treatment and adequate pain management. In conclusion, in a representative nationwide sample in Spain, in patients aged 65 years and older with treated moderate to severe OA pain, said pain was associated with a substantial impact on their functioning in five key domains of patient functioning. Pain severity was the major determinant of disability, and all other study variables decreased as pain severity increased, regardless of the analgesia approach pursued.